Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer

(MedPage Today) -- SAN ANTONIO -- The investigational Trop2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) continued to best chemotherapy in new results from the phase III randomized TROPION-Breast01 trial. Looking...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news